AZD1236 Investigational Drug Fosters Nerve Repair After Spinal Injury
Topic: Spinal Cord Injury (SCI)
Author: University of Birmingham
Published: 2022/07/12 - Updated: 2023/01/04 - Peer-Reviewed: Yes
Contents: Summary - Definition - Introduction - Main - Related
Synopsis: Researchers show that a brain-penetrating candidate drug can foster regeneration of damaged nerves after spinal trauma. This is an exciting time in spinal cord injury research, with several different investigational drugs being identified as potential therapies for spinal cord injury. We are particularly excited about AZD1390, which can be taken orally and reaches the site of injury in sufficient quantities to promote nerve regeneration and restore lost function. Initial studies found that AZD1390 stimulated nerve cell growth in culture and inhibited the ATM protein kinase pathway - a critical biochemical pathway regulating the response to DNA damage.
Introduction
Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as cancer therapy can foster regeneration of damaged nerves after spinal trauma.
Main Digest
The research, published in Clinical and Translational Medicine, used cell and animal models to demonstrate that when taken orally, the candidate drug, known as AZD1390, can block the response to DNA damage in nerve cells and promote regeneration of damaged nerves, so restoring sensory and motor function after spinal injury.
The announcement comes weeks after the same research team showed a different investigational drug (AZD1236) could reduce damage after spinal cord injury by blocking the inflammatory response. Both studies were supported by AstraZeneca's Open Innovations Programme, which shares compounds, tools, technologies, and expertise with the scientific community to advance drug discovery and development.
AZD1390 is also under investigation by AstraZeneca to block ATM-dependent signaling and repair DNA double-strand breaks (DSBs), an action that sensitizes cancer cells to radiation treatment. The DNA Damage Response system (DDR) is activated by DNA damage, including DSBs in the genome, which occur in several common cancers and after spinal cord injury.
Professor Zubair Ahmed from the University's Institute of Inflammation and Ageing and Dr. Richard Tuxworth from the Institute of Cancer and Genomic Sciences hypothesized the persistent activation of this system might prevent recovery from spinal cord injury and that blocking it would promote nerve repair and restore function after injury.
Their initial studies found that AZD1390 stimulated nerve cell growth in culture and inhibited the ATM protein kinase pathway - a critical biochemical pathway regulating the response to DNA damage.
The researchers then used animal models to investigate the effect of AZD1390 following spinal cord injury. Here they showed that oral treatment with AZD1390 resulted in significant suppression of the ATM protein kinase pathway, nerve regeneration beyond the site of injury, and the ability of these nerves to carry electrical signals across the injury site.
Professor Ahmed commented:
"This is an exciting time in spinal cord injury research, with several different investigational drugs being identified as potential therapies for spinal cord injury. We are particularly excited about AZD1390, which can be taken orally and reaches the site of injury in sufficient quantities to promote nerve regeneration and restore lost function.
"Our findings show a remarkable recovery of sensory and motor functions, and AZD1390-treated animals being indistinguishable from uninjured animals within four weeks of injury."
Dr Tuxworth added:
"This early study shows that AZD1390 could be used as a therapy in life-changing conditions. In addition, repurposing this existing investigational drug potentially means we can reach the clinic significantly faster than developing a new drug from scratch."
University of Birmingham Enterprise has filed a patent application covering inhibition of the ATM/Chk2 DNA damage response pathway by compounds such as AZD1390, which may represent a potential therapeutic strategy to foster nerve repair.
Attribution/Source(s):
This peer reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by University of Birmingham, and published on 2022/07/12 (Edit Update: 2023/01/04), the content may have been edited for style, clarity, or brevity. For further details or clarifications, University of Birmingham can be contacted at birmingham.ac.uk. NOTE: Disabled World does not provide any warranties or endorsements related to this article.
Page Information, Citing and Disclaimer
Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.
Cite This Page (APA): University of Birmingham. (2022, July 12 - Last revised: 2023, January 4). AZD1236 Investigational Drug Fosters Nerve Repair After Spinal Injury. Disabled World. Retrieved September 8, 2024 from www.disabled-world.com/disability/types/spinal/azd1390.php
Permalink: <a href="https://www.disabled-world.com/disability/types/spinal/azd1390.php">AZD1236 Investigational Drug Fosters Nerve Repair After Spinal Injury</a>: Researchers show that a brain-penetrating candidate drug can foster regeneration of damaged nerves after spinal trauma.
Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.